Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
Newsletters
Training
White Papers
Advertising
Contact Us
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Levaquin Approved for Pediatric Anthrax Exposure

Drug Industry Daily

May 8, 2008 | Vol. 7 No. 91

Levaquin Approved for Pediatric Anthrax Exposure

The FDA has approved Ortho-McNeil’s antibiotic Levaquin to treat pediatric patients exposed to inhaled anthrax.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

Novartis Gets FDA Approval for Tekturna-Amlodipine Combination FDA Approves Prostate Cancer Drug Jevtana in Eleven Weeks Sanofi’s Prostate Cancer Drug Jevtana Gains FDA Approval Amgen Gets FDA Nod for Prolia to Treat Postmenopausal Osteoporosis

Home
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.